drugset / Trial / NCT03288038

The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia

NCT03288038

Phase 3 Completed 382 enrolled Shin Poong Pharmaceutical Co. Ltd.
RandomizedFactorialDouble-blindTreatment

Summary

A Multi-center, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients with Primary Hypercholesterolemia

Timeline

Start
2014-10-13
Primary completion
2015-11-19
Completion
2015-11-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg
Subject Rosuvastatin Small molecule 5 mg
Subject Rosuvastatin Small molecule 10 mg
Subject Rosuvastatin Small molecule 20 mg

Indications